Activating FLT3 mutations occur in approximately 40% of cytogenetically normal AML patients and the most frequent activating mutations is FLT3-ITD, whose presence is associated with resistence to chemotherapy and inferior outcome [22]. This evidence concerns the gene FLT3 and acute myeloid leukemia.